CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 23412-23651 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"In patients with documented HAHA and/or IgE-mediated reactions to trastuzumab and clinical symptoms of type I/mast cell mediator-related symptoms, desensitization can allow continued administration of this treatment by providing tolerance.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T245","span":{"begin":0,"end":239},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T245","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"Epistemic_Statements","denotations":[{"id":"T32","span":{"begin":0,"end":239},"obj":"Epistemic_statement"}],"attributes":[{"subj":"T32","pred":"source","obj":"Epistemic_Statements"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T245","span":{"begin":0,"end":239},"obj":"Sentence"}],"attributes":[{"subj":"T245","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#beec93","default":true},{"id":"Epistemic_Statements","color":"#ec93d9"},{"id":"CORD-19_Custom_license_subset","color":"#93ece5"}]}]}}